recombinant human il 2 (InvivoGen)
Structured Review
Recombinant Human Il 2, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 39 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+il-6/Recombinant+human+IL-6/pm42018652-207-22-19
Average 94 stars, based on 39 article reviews
Images
Related Articles
Isolation:Article Title: NLRP3 inhibition by VTX3232 tempers inflammation resulting in reduced body weight, hyperglycemia, and hepatic steatosis in obese male mice Article Snippet: (final concentration (f.c.)), and 6.25 ng/mL selenous acid (f.c.), and 25 % HHCM with 5 % heat-inactivated human serum, supplemented or not with palmitic acid (Sanbio, #29558-5, 62.5 μM f.c.), IL-1β ( Recombinant:Article Title: NLRP3 inhibition by VTX3232 tempers inflammation resulting in reduced body weight, hyperglycemia, and hepatic steatosis in obese male mice Article Snippet: (final concentration (f.c.)), and 6.25 ng/mL selenous acid (f.c.), and 25 % HHCM with 5 % heat-inactivated human serum, supplemented or not with palmitic acid (Sanbio, #29558-5, 62.5 μM f.c.), IL-1β ( Activity Assay:Article Title: NLRP3 inhibition by VTX3232 tempers inflammation resulting in reduced body weight, hyperglycemia, and hepatic steatosis in obese male mice Article Snippet: (final concentration (f.c.)), and 6.25 ng/mL selenous acid (f.c.), and 25 % HHCM with 5 % heat-inactivated human serum, supplemented or not with palmitic acid (Sanbio, #29558-5, 62.5 μM f.c.), IL-1β ( Enzymatic Assay:Article Title: NLRP3 inhibition by VTX3232 tempers inflammation resulting in reduced body weight, hyperglycemia, and hepatic steatosis in obese male mice Article Snippet: (final concentration (f.c.)), and 6.25 ng/mL selenous acid (f.c.), and 25 % HHCM with 5 % heat-inactivated human serum, supplemented or not with palmitic acid (Sanbio, #29558-5, 62.5 μM f.c.), IL-1β ( |
